Increasing evidence validates that dying tumor cells following chemotherapy might activate the NLRP3 inflammasome of dendritic cells via P2×7 purinergic receptors, thus priming tumor-specific interferon-γ-producing T lymphocytes to limit cancer growth [119]. This evidence concerns the gene NLRP3 and cancer.